التفاصيل البيبلوغرافية
| العنوان: |
A Multicenter Randomized Trial Assessing the Efficacy of Helium/Oxygen in Severe Exacerbations of Chronic Obstructive Pulmonary Disease. |
| المؤلفون: |
Jolliet, Philippe, Ouanes-Besbes, Lamia, Abroug, Fekri, Khelil, Jalila Ben, Besbes, Mohamed, Garnero, Aude, Arnal, Jean-Michel, Daviaud, Fabrice, Chiche, Jean-Daniel, Lortat-Jacob, Benoît, Diehl, Jean-Luc, Lerolle, Nicolas, Mercat, Alain, Razazi, Keyvan, Brun-Buisson, Christian, Durand-Zaleski, Isabelle, Texereau, Joëlle, Brochard, Laurent, Ben Khelil, Jalila, E.C.H.O.ICU Trial Investigators |
| المصدر: |
American Journal of Respiratory & Critical Care Medicine; 4/1/2017, Vol. 195 Issue 7, p871-880, 10p, 1 Diagram, 3 Charts, 4 Graphs |
| مصطلحات موضوعية: |
HELIUM, OBSTRUCTIVE lung disease treatment, OXYGEN therapy, ARTIFICIAL respiration, BLOOD gases analysis, COMPARATIVE studies, HOSPITAL care, LENGTH of stay in hospitals, LONGITUDINAL method, OBSTRUCTIVE lung diseases, RESEARCH methodology, MEDICAL cooperation, RESEARCH, DISEASE relapse, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, THERAPEUTICS |
| مستخلص: |
Rationale: During noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the work of breathing and hypercapnia more than air/O2, but its impact on clinical outcomes remains unknown.Objectives: To determine whether continuous administration of heliox for 72 hours, during and in-between NIV sessions, was superior to air/O2 in reducing NIV failure (25-15%) in severe hypercapnic COPD exacerbations.Methods: This was a prospective, randomized, open-label trial in 16 intensive care units (ICUs) and 6 countries. Inclusion criteria were COPD exacerbations with PaCO2 ≥ 45 mm Hg, pH ≤ 7.35, and at least one of the following: respiratory rate ≥ 25/min, PaO2 ≤ 50 mm Hg, and oxygen saturation (arterial [SaO2] or measured by pulse oximetry [SpO2]) ≤ 90%. A 6-month follow-up was performed.Measurements and Main Results: The primary endpoint was NIV failure (intubation or death without intubation in the ICU). The secondary endpoints were physiological parameters, duration of ventilation, duration of ICU and hospital stay, 6-month recurrence, and rehospitalization rates. The trial was stopped prematurely (445 randomized patients) because of a low global failure rate (NIV failure: air/O2 14.5% [n = 32]; heliox 14.7% [n = 33]; P = 0.97, and time to NIV failure: heliox group 93 hours [n = 33], air/O2 group 52 hours [n = 32]; P = 0.12). Respiratory rate, pH, PaCO2, and encephalopathy score improved significantly faster with heliox. ICU stay was comparable between the groups. In patients intubated after NIV failed, patients on heliox had a shorter ventilation duration (7.4 ± 7.6 d vs. 13.6 ± 12.6 d; P = 0.02) and a shorter ICU stay (15.8 ± 10.9 d vs. 26.7 ± 21.0 d; P = 0.01). No difference was observed in ICU and 6-month mortality.Conclusions: Heliox improves respiratory acidosis, encephalopathy, and the respiratory rate more quickly than air/O2 but does not prevent NIV failure. Overall, the rate of NIV failure was low. Clinical trial registered with www.clinicaltrials.gov (NCT 01155310). [ABSTRACT FROM AUTHOR] |
|
Copyright of American Journal of Respiratory & Critical Care Medicine is the property of American Thoracic Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder